

37. (Amended) A method for treating an autoimmune disease in a human or rodent host by suppressing an autoimmune response associated with said disease, the method comprising administering by nose or mouth to said [human] host an effective amount for [treating said disease] suppressing said response of a composition comprising a bystander antigen, wherein said bystander antigen is not an [autoantigen in said human] antigen to which T cells which mediate the disease are sensitized and wherein said bystander antigen is not an insulin antigen.

38. (Unchanged) The method of claim 37 wherein said bystander antigen is specific to an organ or tissue afflicted by immune attack during said disease.

Cancel claim 39 without prejudice or disclaimer.

42. (Amended) The method of claim 37 wherein said bystander is administered to said [human] host in aerosol form.

43. (Unchanged) The method of claim 37 wherein said bystander antigen is administered in a dry powder form.

44. (Unchanged) The method of claim 37 wherein said bystander antigen is administered as a saline solution.

Cancel claim 45 without prejudice or disclaimer.

46. (Amended) The method of claim 38 wherein said disease is Type I diabetes and said bystander antigen is glucagon, administered orally.

Cancel claim 47 without prejudice or disclaimer.

48. (Amended) A pharmaceutical dosage form for ^{suppressing} treating an

autoimmune disease in a human or rodent, the form consisting essentially of:

an effective amount for treating said disease of a bystander
antigen; and a pharmaceutically acceptable carrier or diluent;

wherein said bystander antigen is not insulin nor an antigen to which T cells that
mediate said disease are sensitized [an autoantigen in said human], and wherein
said dosage form is contained in an inhaler or nebulizer.

49. (Unchanged) The pharmaceutical dosage form of claim 48
wherein said bystander antigen is specific to an organ or tissue afflicted by immune
attack during said disease.

52. (Unchanged) The pharmaceutical dosage form of claim 49
wherein said dosage form is an aerosol form.

53. (Unchanged) The pharmaceutical dosage form of claim 49
wherein said dosage form is a saline solution.

54. (Unchanged) The pharmaceutical dosage form of claim 49
wherein said dosage form is a dry powder.

Cancel claim 55 without prejudice or disclaimer.

56. (Unchanged) The pharmaceutical dosage form of claim 48
wherein said disease is selected from the group consisting of Type I diabetes and
animal models therefor and said bystander antigen is glucagon.

57. (Unchanged) A pharmaceutical dosage form for nasal
administration for treating Type I diabetes in a human comprising an effective amount